Trialynx founder and CEO Angela Schwab continues her conversation with PharmExec and explains the effective ways that AI is being used to tackle common problems with clinical trial design.
Angela Schwab
Advertisement
Articles by Angela Schwab
Angela Schwab, founder and CEO of Trialynx, discusses the current state of AI in the pharmaceutical industry and why it’s important for companies to demonstrate the true value of their AI-based products.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
GSK Enters Multi-Year Collaboration with Helix to Develop Precision Medications
2
Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million
3
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5